David W. Gjertson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David W. Gjertson has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Elaine F. Reed
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA
5 shared publications - Jerzy W. Kupiec-Weglinski
The Dumont-UCLA Transplantation Center, Department of Surgery, Division of Liver and Pancreas Transplantation, David Geffen School of Medicine, UCLA
4 shared publications - Rebecca A. Sosa
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
4 shared publications - Fady M. Kaldas
Department of Surgery, University of California Los Angeles, Los Angeles, California, USA
3 shared publications - Ronald W. Busuttil
Department of Surgery, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
3 shared publications - Ying Zheng
Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA
3 shared publications
Latest Publications
- Open Access
- 9 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 1858-1871
Disulfide-HMGB1 signals through TLR4 and TLR9 to induce inflammatory macrophages capable of innate-adaptive crosstalk in human liver transplantation
- 9 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 1858-1871
Open AccessDisulfide-HMGB1 signals through TLR4 and TLR9 to induce inflammatory macrophages capable of innate-adaptive crosstalk in human liver transplantation
- Open Access
- 8 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (21)
NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant
CMV causes mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals can be life-threatening. CMV viremia often occurs in solid organ transplant recipients and associates with decreased graft survival and higher mortality. Furthering understanding of impaired immunity that allows CMV reactivation is critical to guiding antiviral therapy and examining the effect of CMV on solid organ transplant outcomes. This study characterized longitudinal immune responses to CMV in 31 kidney transplant recipients with CMV viremia and matched, nonviremic recipients. Recipients were sampled 3 and 12 months after transplant, with additional samples 1 week and 1 month after viremia. PBMCs were stained for NK and T cell markers. PBMC transcriptomes were characterized by RNA-Seq. Plasma proteins were quantified by Luminex. CD8 + T cell transcriptomes were characterized by single-cell RNA-Seq. Before viremia, patients had high levels of IL-15 with concurrent expansion of immature CD56 bright NK cells. After viremia, mature CD56 dim NK cells and CD28 – CD8 + T cells upregulating inhibitory and NK-associated receptors were expanded. Memory NK cells and NK-like CD28 – CD8 + T cells were associated with control of viremia. These findings suggest that signatures of innate activation may be prognostic for CMV reactivation after transplant, while CD8 + T cell functionality is critical for effective control of CMV.
- 8 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (21)
Open AccessNK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant
CMV causes mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals can be life-threatening. CMV viremia often occurs in solid organ transplant recipients and associates with decreased graft survival and higher mortality. Furthering understanding of impaired immunity that allows CMV reactivation is critical to guiding antiviral therapy and examining the effect of CMV on solid organ transplant outcomes. This study characterized longitudinal immune responses to CMV in 31 kidney transplant recipients with CMV viremia and matched, nonviremic recipients. Recipients were sampled 3 and 12 months after transplant, with additional samples 1 week and 1 month after viremia. PBMCs were stained for NK and T cell markers. PBMC transcriptomes were characterized by RNA-Seq. Plasma proteins were quantified by Luminex. CD8 + T cell transcriptomes were characterized by single-cell RNA-Seq. Before viremia, patients had high levels of IL-15 with concurrent expansion of immature CD56 bright NK cells. After viremia, mature CD56 dim NK cells and CD28 – CD8 + T cells upregulating inhibitory and NK-associated receptors were expanded. Memory NK cells and NK-like CD28 – CD8 + T cells were associated with control of viremia. These findings suggest that signatures of innate activation may be prognostic for CMV reactivation after transplant, while CD8 + T cell functionality is critical for effective control of CMV.
- Open Access
- 23 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (5) , 2689-2704
Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury
Although CEACAM1 (CC1) glycoprotein resides at the interface of immune liver injury and metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains elusive. We aimed to determine whether/how CEACAM1 signaling may affect hepatic ischemia-reperfusion injury (IRI) and OLT outcomes. In the mouse, donor liver CC1 null mutation augmented IRI-OLT (CC1-KO→WT) by enhancing ROS expression and HMGB1 translocation during cold storage, data supported by in vitro studies where hepatic flush from CC1-deficient livers enhanced macrophage activation in bone marrow–derived macrophage cultures. Although hepatic CC1 deficiency augmented cold stress–triggered ASK1/p-p38 upregulation, adjunctive ASK1 inhibition alleviated IRI and improved OLT survival by suppressing p-p38 upregulation, ROS induction, and HMGB1 translocation (CC1-KO→WT), whereas ASK1 silencing (siRNA) promoted cytoprotection in cold-stressed and damage-prone CC1-deficient hepatocyte cultures. Consistent with mouse data, CEACAM1 expression in 60 human donor liver biopsies correlated negatively with activation of the ASK1/p-p38 axis, whereas low CC1 levels associated with increased ROS and HMGB1 translocation, enhanced innate and adaptive immune responses, and inferior early OLT function. Notably, reduced donor liver CEACAM1 expression was identified as one of the independent predictors for early allograft dysfunction (EAD) in human OLT patients. Thus, as a checkpoint regulator of IR stress and sterile inflammation, CEACAM1 may be considered as a denominator of donor hepatic tissue quality, and a target for therapeutic modulation in OLT recipients.
- 23 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (5) , 2689-2704
Open AccessHepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury
Although CEACAM1 (CC1) glycoprotein resides at the interface of immune liver injury and metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains elusive. We aimed to determine whether/how CEACAM1 signaling may affect hepatic ischemia-reperfusion injury (IRI) and OLT outcomes. In the mouse, donor liver CC1 null mutation augmented IRI-OLT (CC1-KO→WT) by enhancing ROS expression and HMGB1 translocation during cold storage, data supported by in vitro studies where hepatic flush from CC1-deficient livers enhanced macrophage activation in bone marrow–derived macrophage cultures. Although hepatic CC1 deficiency augmented cold stress–triggered ASK1/p-p38 upregulation, adjunctive ASK1 inhibition alleviated IRI and improved OLT survival by suppressing p-p38 upregulation, ROS induction, and HMGB1 translocation (CC1-KO→WT), whereas ASK1 silencing (siRNA) promoted cytoprotection in cold-stressed and damage-prone CC1-deficient hepatocyte cultures. Consistent with mouse data, CEACAM1 expression in 60 human donor liver biopsies correlated negatively with activation of the ASK1/p-p38 axis, whereas low CC1 levels associated with increased ROS and HMGB1 translocation, enhanced innate and adaptive immune responses, and inferior early OLT function. Notably, reduced donor liver CEACAM1 expression was identified as one of the independent predictors for early allograft dysfunction (EAD) in human OLT patients. Thus, as a checkpoint regulator of IR stress and sterile inflammation, CEACAM1 may be considered as a denominator of donor hepatic tissue quality, and a target for therapeutic modulation in OLT recipients.
- Open Access
- 14 September 2019
- Published by Springer Nature in BMC Immunology
- Vol. 20 (1) , 1-11
Biological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests
Background: Cytokines, chemokines, adipocytokines, soluble cell receptors, and immune activation markers play an important role in immune responsiveness and can provide prognostic value since they reflect underlying conditions and disease states. This study was undertaken to investigate the components of biological variation for various laboratory tests of blood immunological biomarkers.Results: Estimates of intra-individual coefficient of variation (CVI) and inter-individual coefficient of variation (CVG) were examined for blood immunological biomarkers. Biomarkers with CVI < 10% for both genders were CD3, CD4, and CD8 T-cells, serum levels of soluble cluster of differentiation 14 (sCD14), sCD163, and soluble glycoprotein 130 (sgp130). The CVIfor serum levels of adiponectin, interleukin-1 receptor antagonist (IL-1Ra), macrophage inflammatory protein 1 beta (MIP-1β), soluble CD40 Ligand (sCD40L), soluble interleukin-2 receptor alpha (sIL-2Rα), soluble interleukin-6 receptor (sIL-6R), soluble tumor necrosis factor receptor II (sTNF-RII), and tumor necrosis factor alpha (TNF-α) were between 11 and 20%. Biomarkers with CVG < 20% were CD3 T-cell, and serum concentrations of sCD14, sCD40L, and sgp130. The biomarkers with CVG > 40% were adiponectin, IL-1ra, leptin, MIP-1β, sCD163, and sIL-2Rα.Conclusion: The biological variations of biomarkers have important monitoring value for longitudinal investigation and are essential for quality specification of tests that are performed in the laboratory. The CVIwas relatively small while CVGwas comparatively large and mean values of each biomarker vary between subjects. The individuality of biomarkers significantly influences reference interval values. A majority of the biomarkers in this study had strong individuality and the result of each biomarker should be cautiously interpreted if using established reference interval values. Comparison of a patient’s test result with previous ones may be more useful than the usage of conventional reference values.
- 14 September 2019
- Published by Springer Nature in BMC Immunology
- Vol. 20 (1) , 1-11
Open AccessBiological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests
Background: Cytokines, chemokines, adipocytokines, soluble cell receptors, and immune activation markers play an important role in immune responsiveness and can provide prognostic value since they reflect underlying conditions and disease states. This study was undertaken to investigate the components of biological variation for various laboratory tests of blood immunological biomarkers.Results: Estimates of intra-individual coefficient of variation (CVI) and inter-individual coefficient of variation (CVG) were examined for blood immunological biomarkers. Biomarkers with CVI < 10% for both genders were CD3, CD4, and CD8 T-cells, serum levels of soluble cluster of differentiation 14 (sCD14), sCD163, and soluble glycoprotein 130 (sgp130). The CVIfor serum levels of adiponectin, interleukin-1 receptor antagonist (IL-1Ra), macrophage inflammatory protein 1 beta (MIP-1β), soluble CD40 Ligand (sCD40L), soluble interleukin-2 receptor alpha (sIL-2Rα), soluble interleukin-6 receptor (sIL-6R), soluble tumor necrosis factor receptor II (sTNF-RII), and tumor necrosis factor alpha (TNF-α) were between 11 and 20%. Biomarkers with CVG < 20% were CD3 T-cell, and serum concentrations of sCD14, sCD40L, and sgp130. The biomarkers with CVG > 40% were adiponectin, IL-1ra, leptin, MIP-1β, sCD163, and sIL-2Rα.Conclusion: The biological variations of biomarkers have important monitoring value for longitudinal investigation and are essential for quality specification of tests that are performed in the laboratory. The CVIwas relatively small while CVGwas comparatively large and mean values of each biomarker vary between subjects. The individuality of biomarkers significantly influences reference interval values. A majority of the biomarkers in this study had strong individuality and the result of each biomarker should be cautiously interpreted if using established reference interval values. Comparison of a patient’s test result with previous ones may be more useful than the usage of conventional reference values.
- Open Access
- 27 March 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (5) , 1689-1699
Clinical efficacy of gene-modified stem cells in adenosine deaminase–deficient immunodeficiency
BACKGROUND. Autologous hematopoietic stem cell transplantation (HSCT) of gene-modified cells is an alternative to enzyme replacement therapy (ERT) and allogeneic HSCT that has shown clinical benefit for adenosine deaminase–deficient (ADA-deficient) SCID when combined with reduced intensity conditioning (RIC) and ERT cessation. Clinical safety and therapeutic efficacy were evaluated in a phase II study. METHODS. Ten subjects with confirmed ADA-deficient SCID and no available matched sibling or family donor were enrolled between 2009 and 2012 and received transplantation with autologous hematopoietic CD34+ cells that were modified with the human ADA cDNA (MND-ADA) γ-retroviral vector after conditioning with busulfan (90 mg/m2) and ERT cessation. Subjects were followed from 33 to 84 months at the time of data analysis. Safety of the procedure was assessed by recording the number of adverse events. Efficacy was assessed by measuring engraftment of gene-modified hematopoietic stem/progenitor cells, ADA gene expression, and immune reconstitution. RESULTS. With the exception of the oldest subject (15 years old at enrollment), all subjects remained off ERT with normalized peripheral blood mononuclear cell (PBMC) ADA activity, improved lymphocyte numbers, and normal proliferative responses to mitogens. Three of nine subjects were able to discontinue intravenous immunoglobulin replacement therapy. The MND-ADA vector was persistently detected in PBMCs (vector copy number [VCN] = 0.1–2.6) and granulocytes (VCN = 0.01–0.3) through the most recent visits at the time of this writing. No patient has developed a leukoproliferative disorder or other vector-related clinical complication since transplant. CONCLUSION. These results demonstrate clinical therapeutic efficacy from gene therapy for ADA-deficient SCID, with an excellent clinical safety profile. TRIAL REGISTRATION. ClinicalTrials.gov NCT00794508. FUNDING. Food and Drug Administration Office of Orphan Product Development award, RO1 FD003005; NHLBI awards, PO1 HL73104 and Z01 HG000122; UCLA Clinical and Translational Science Institute awards, UL1RR033176 and UL1TR000124.
- 27 March 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (5) , 1689-1699
Open AccessClinical efficacy of gene-modified stem cells in adenosine deaminase–deficient immunodeficiency
BACKGROUND. Autologous hematopoietic stem cell transplantation (HSCT) of gene-modified cells is an alternative to enzyme replacement therapy (ERT) and allogeneic HSCT that has shown clinical benefit for adenosine deaminase–deficient (ADA-deficient) SCID when combined with reduced intensity conditioning (RIC) and ERT cessation. Clinical safety and therapeutic efficacy were evaluated in a phase II study. METHODS. Ten subjects with confirmed ADA-deficient SCID and no available matched sibling or family donor were enrolled between 2009 and 2012 and received transplantation with autologous hematopoietic CD34+ cells that were modified with the human ADA cDNA (MND-ADA) γ-retroviral vector after conditioning with busulfan (90 mg/m2) and ERT cessation. Subjects were followed from 33 to 84 months at the time of data analysis. Safety of the procedure was assessed by recording the number of adverse events. Efficacy was assessed by measuring engraftment of gene-modified hematopoietic stem/progenitor cells, ADA gene expression, and immune reconstitution. RESULTS. With the exception of the oldest subject (15 years old at enrollment), all subjects remained off ERT with normalized peripheral blood mononuclear cell (PBMC) ADA activity, improved lymphocyte numbers, and normal proliferative responses to mitogens. Three of nine subjects were able to discontinue intravenous immunoglobulin replacement therapy. The MND-ADA vector was persistently detected in PBMCs (vector copy number [VCN] = 0.1–2.6) and granulocytes (VCN = 0.01–0.3) through the most recent visits at the time of this writing. No patient has developed a leukoproliferative disorder or other vector-related clinical complication since transplant. CONCLUSION. These results demonstrate clinical therapeutic efficacy from gene therapy for ADA-deficient SCID, with an excellent clinical safety profile. TRIAL REGISTRATION. ClinicalTrials.gov NCT00794508. FUNDING. Food and Drug Administration Office of Orphan Product Development award, RO1 FD003005; NHLBI awards, PO1 HL73104 and Z01 HG000122; UCLA Clinical and Translational Science Institute awards, UL1RR033176 and UL1TR000124.
- 27 November 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (10) , 1349-1350
For an Always Promising Transplant Prediction, Call ANN
With apologies to Sherlock Holmes, “You can never foretell when any one man’s kidney transplant will fail, but you can say with precision when an average number will fail. … So says the statistician.”
- 27 November 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (10) , 1349-1350
For an Always Promising Transplant Prediction, Call ANN
With apologies to Sherlock Holmes, “You can never foretell when any one man’s kidney transplant will fail, but you can say with precision when an average number will fail. … So says the statistician.”
- 1 September 2002
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (6) , 2432
Impact of delayed graft function and acute rejection on graft survival
- 1 September 2002
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (6) , 2432
Impact of delayed graft function and acute rejection on graft survival
- Open Access
- 1 January 2002
- Published by Elsevier in American Journal of Transplantation
- Vol. 2 (1) , 84-93
Four Causes of Cadaveric Kidney Transplant Failure: A Competing Risk Analysis
Multiple pathological processes are responsible for renal transplant loss. Development of effective prophylactic regimens requires that risks associated with different outcomes be assessed when several processes act together. A multistate competing risk model that derived multiple endpoint probabilities without averaging impacts of covariates over different outcomes or overestimating fractions of survivors was used to estimate the influence of 16 factors simultaneously on four failure types (acute rejection, chronic rejection, death with a functioning graft and all other causes combined). We analyzed 12,413 non-Black and 5,121 Black patients undergoing primary cadaveric kidney transplantation reported to UNOS during 1994-96. Black recipients generally demonstrated higher rates of failure, but the method provided joint probabilities for each failure type and covariate level. To illustrate, a middle-aged Black recipient had probabilities of 6.5%, 5.9%, 2.6% and 6.6% to experience acute rejection failure, chronic rejection failure, death with a functioning graft and other failures, respectively, within 3 years. The corresponding non-Black's chances were 2.9%, 2.5%, 2.7% and 3.6%. The overall 3-year survival equaled 78.4% [100%-(6.5% + 5.9% + 2.6% + 6.6%)] and 88.3% for Blacks and non-Blacks, respectively. The growing complexity of transplantation will benefit from new analytic approaches that accommodate multiple transitions along diverse paths to eventual graft loss or death.
- 1 January 2002
- Published by Elsevier in American Journal of Transplantation
- Vol. 2 (1) , 84-93
Open AccessFour Causes of Cadaveric Kidney Transplant Failure: A Competing Risk Analysis
Multiple pathological processes are responsible for renal transplant loss. Development of effective prophylactic regimens requires that risks associated with different outcomes be assessed when several processes act together. A multistate competing risk model that derived multiple endpoint probabilities without averaging impacts of covariates over different outcomes or overestimating fractions of survivors was used to estimate the influence of 16 factors simultaneously on four failure types (acute rejection, chronic rejection, death with a functioning graft and all other causes combined). We analyzed 12,413 non-Black and 5,121 Black patients undergoing primary cadaveric kidney transplantation reported to UNOS during 1994-96. Black recipients generally demonstrated higher rates of failure, but the method provided joint probabilities for each failure type and covariate level. To illustrate, a middle-aged Black recipient had probabilities of 6.5%, 5.9%, 2.6% and 6.6% to experience acute rejection failure, chronic rejection failure, death with a functioning graft and other failures, respectively, within 3 years. The corresponding non-Black's chances were 2.9%, 2.5%, 2.7% and 3.6%. The overall 3-year survival equaled 78.4% [100%-(6.5% + 5.9% + 2.6% + 6.6%)] and 88.3% for Blacks and non-Blacks, respectively. The growing complexity of transplantation will benefit from new analytic approaches that accommodate multiple transitions along diverse paths to eventual graft loss or death.